Analysis of immune status in non-small cell lung cancer patients with EGFR mutations

Analysis of immune status in non-small cell lung cancer patients with EGFR mutations - Analysis of immune status in NSCLC with EGFR mutations

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031076

Enrollment

Registered

2018-02-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with advanced EGFR-mutated NSCLC receiving EGFR-TKIs as 1st line treatment whose tumor samples pre- and post-treatment are surplus will be enrolled in this study. Patients who already treated EGFR-TKI with archive samples will be also enrolled in this study.

Exclusion criteria

Exclusion criteria: Patients who are not feasible for biopsy will be excluded.

Design outcomes

Primary

Measure	Time frame
Changes of immune cells in tumor-infiltrating lymphocytes from pre- to post-treatment with EGFR-TKIs.	—

Countries

Japan

Contacts

Public ContactYosuke Togashi

National Cancer Center Division of Cancer Immunology

ytogashi1584@gmail.com0471331111

Outcome results